Balance Sheet
Accounts PayablesAccumulated DepreciationAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Protagonist Therapeutics (PTGX) Operating Leases (2019 - 2025)

Protagonist Therapeutics' Operating Leases history spans 7 years, with the latest figure at $8.0 million for Q4 2025.

  • For Q4 2025, Operating Leases fell 22.36% year-over-year to $8.0 million; the TTM value through Dec 2025 reached $8.0 million, down 22.36%, while the annual FY2025 figure was $8.0 million, 22.36% down from the prior year.
  • Operating Leases for Q4 2025 was $8.0 million at Protagonist Therapeutics, down from $8.5 million in the prior quarter.
  • Across five years, Operating Leases topped out at $11.0 million in Q2 2024 and bottomed at $462000.0 in Q1 2023.
  • The 5-year median for Operating Leases is $4.1 million (2021), against an average of $5.4 million.
  • The largest annual shift saw Operating Leases fell 13.24% in 2021 before it crashed 84.91% in 2023.
  • A 5-year view of Operating Leases shows it stood at $3.7 million in 2021, then tumbled by 68.81% to $1.1 million in 2022, then plummeted by 59.51% to $462000.0 in 2023, then soared by 2141.56% to $10.4 million in 2024, then fell by 22.36% to $8.0 million in 2025.
  • Per Business Quant, the three most recent readings for PTGX's Operating Leases are $8.0 million (Q4 2025), $8.5 million (Q3 2025), and $9.1 million (Q2 2025).